Literature DB >> 10542439

Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery.

H V Gelboin1, K W Krausz, F J Gonzalez, T J Yang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10542439     DOI： 10.1016/s0165-6147(99)01382-6

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  5 in total

1.  Biomedical aspects of metabolic portraiture.

Authors:  L A Piruzyan; V A Sukhanov; E V Kalinina; A N Saprin
Journal:  Dokl Biochem Biophys       Date:  2001 Mar-Apr       Impact factor: 0.788

Review 2.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

3.  Identification of metabolites of dalfampridine (4-aminopyridine) in human subjects and reaction phenotyping of relevant cytochrome P450 pathways.

Authors:  Anthony Caggiano; Andrew Blight
Journal:  J Drug Assess       Date:  2013-08-14

Review 4.  Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.

Authors:  M Teresa Donato; José V Castell
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

Review 5.  COVID-19 Vaccine: A comprehensive status report.

Authors:  Simran Preet Kaur; Vandana Gupta
Journal:  Virus Res       Date:  2020-08-13       Impact factor: 3.303
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.